Exothera is a CDMO dedicated to virus and viral vector production. As a Univercells company, Exothera provides best-in-class bioprocessing expertise that capitalizes on novel manufacturing technologies. The company delivers accelerated process development/optimization to rapidly reach GMP clinical and commercial production of virus and viral vectors. With in-house and tech transfer options, our experienced team is dedicated to delivering the best approach with the flexibility you need to accelerate and achieve success.
Exothera has developed its expertise to support development and industrialization projects and can offer support during all phases of process development and manufacturing. Exothera’s DNA is to use innovative development principles such as highly concentrated and continuous processing to increase process performance and reduce operating costs.
Our experienced team has conducted successful process development, optimization, scale-up and technology transfer projects while at Univercells, building a strong track record and know-how that drove the creation of a dedicated service company.
Starting with its flagship project supported by the Bill & Melinda Gates Foundation, the team developed and scaled-up optimized production of Sabin trivalent inactivated polio vaccine (sIPV) delivering high yields and low costs of goods. We are applying our process knowledge to optimize key process parameters for gene therapies, several projects demonstrated high performance with the main viral vectors in use (adenovirus, AAV, lentivirus).
To fully meet our clients’ needs, Exothera has structured its workforce in different collaborative platforms (Upstream, Downstream, Analytical Science and QC, Manufacturing) led by subject matter experts. Exothera’s team is fully dedicated to serving academic and industry partners.
www.exothera.world
